Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the appointment of Mark Daniels to the newly created position of chief ethics and compliance officer.
Daniels will maintain his current position as Twist Bioscience’s general counsel. In his expanded role, he will oversee the company’s ethics and compliance programs.
“Our expanding role in the bioeconomy comes with incredible responsibility to continuously evaluate the ethical impact of our business and our actions,” said Twist Bioscience CEO Emily Leproust. “Importantly, we view ethics and compliance as integral to our operations, with a continued focus on demonstrated leadership in biosecurity and biosafety. Ethics and compliance will only become more important as we move forward with our pharmaceutical vertical.”
Daniels joined Twist Bioscience in August 2016, bringing more than 25 years of experience as a seasoned legal officer with extensive technology and biotechnology industry expertise at Fortune 500 companies. Prior to joining Twist Bioscience, he was vice president, law and deputy chief corporate compliance officer at Broadcom. Before that, he spent 20 years in positions of increasing responsibility in the legal department at Amgen, where his last role was vice president and associate general counsel.